Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials

Treatment of inoperable or non-operated locally advanced head and neck squamous cell carcinomas (HNSCC)is typically based on radiotherapy (RT) delivering 70Gy/7weeks combined with chemotherapy [1]. Indeed, concurrent chemoradiotherapy (CRT) has become a standard treatment of locally advanced HNSCC, as reported in the meta-Analysis of Chemotherapy in Head & Neck Cancer (MACH-NC) with an absolute 5-year survival benefit of 6.5% [2]. In another meta-analysis, altered fractionated radiotherapy (AFRT) was associated with an absolute 5-year survival benefit of 3.4% [3].

http://ift.tt/2srFhs8